Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML These findings underscore the need to screen for and address mental health concerns among AYA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback